Volker Diehl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Volker Diehl has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Daniel Re
Department of Internal Medicine I, University Hospital of Cologne, Kerpenerstr. 62, 50931 Cologne, Germany
3 shared publications- Jeremy Franklin
Institute of Medical Statistics, Informatics, and Epidemiology, University of Cologne Medical School, Cologne, Germany
3 shared publications Andreas Josting
First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
2 shared publications- K. Behringer
German Hodgkin Study Group, Köln, Deutschland
2 shared publications M. Sieber
Klinik I für Innere Medizin, Universität zu Köln DE
2 shared publicationsPeter Borchmann
2 shared publications
Latest Publications
- 5 December 2014
- Published by Springer Nature
- p. 235-250
Treatment of Advanced-Stage Hodgkin Lymphoma
- 1 February 2014
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 28 (1)
Preface
- 1 February 2014
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 28 (1)
Preface
- 25 November 2013
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 28 (1) , 1-11
First Hodgkin Cell Line L428 and the CD30 Antigen
- 25 November 2013
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 28 (1) , 1-11
First Hodgkin Cell Line L428 and the CD30 Antigen
- 10 May 2011
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 6 (3) , 164-171
The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma
In recent decades, the prognosis of Hodgkin lymphoma has been substantially improved, but these successes have been restricted to younger patients and could not be translated into a major benefit for older patients, especially those with advanced-stage disease. Major problems in treating older patients include a different biology, frailty, comorbidities, and poorer tolerance of therapy. Additionally, these patients are often excluded from randomized trials, so an evidence-based standard of care is lacking. Importantly, the proportion of older patients with HL will increase over the next 50 years. Currently, ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine) is considered to be the gold standard, even though it has some toxicity in older patients and prospective data are not available. Thus, further studies are required, including the assessment of comorbidities and the incorporation of new drugs such as immunomodulatory agents, antibody-drug conjugates, mTOR inhibitors, or histone deacetylase (HDAC) inhibitors.
- 10 May 2011
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 6 (3) , 164-171
The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma
In recent decades, the prognosis of Hodgkin lymphoma has been substantially improved, but these successes have been restricted to younger patients and could not be translated into a major benefit for older patients, especially those with advanced-stage disease. Major problems in treating older patients include a different biology, frailty, comorbidities, and poorer tolerance of therapy. Additionally, these patients are often excluded from randomized trials, so an evidence-based standard of care is lacking. Importantly, the proportion of older patients with HL will increase over the next 50 years. Currently, ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine) is considered to be the gold standard, even though it has some toxicity in older patients and prospective data are not available. Thus, further studies are required, including the assessment of comorbidities and the incorporation of new drugs such as immunomodulatory agents, antibody-drug conjugates, mTOR inhibitors, or histone deacetylase (HDAC) inhibitors.
- Open Access
- 1 November 2010
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (11) , 3739
Henry Kaplan and the story of Hodgkin’s disease
- 1 November 2010
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (11) , 3739
Open AccessHenry Kaplan and the story of Hodgkin’s disease
- 1 June 2010
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 7 (6) , 301-302
Are macrophages the bad guys in Hodgkin lymphoma?
Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumor-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be a major step towards personalized therapy for patients with Hodgkin lymphoma.
- 1 June 2010
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 7 (6) , 301-302
Are macrophages the bad guys in Hodgkin lymphoma?
Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumor-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be a major step towards personalized therapy for patients with Hodgkin lymphoma.
- Open Access
- 1 January 2009
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2009 (1) , 320-325
The bridge between patient and doctor: the shift from CAM to integrative medicine
Integrative medicine (IM) has become a major challenge for doctors and nurses, as well as psychologists and many other disciplines involved in the endeavor to help patients to better tolerate the burden of toxic therapies and give patients tools so they can actively participate in their “salutogenesis.” IM encompasses psycho-oncology, acupuncture, and physical and mental exercises to restore vital capacities lost due to toxic therapies; furthermore, it aims to replenish nutritional and metabolic deficits during and after cancer treatment. IM gains an ever increasing importance in the face of the rapidly growing number of cancer survivors demanding more than just evidence-based diagnostic and therapeutic strategies. IM has to prove its value and justification by filling the gap between unproven methods of alternative medicine, still used by many cancer patients, and academic conventional medicine, which often does not satisfy the emotional and spiritual needs of cancer patients.
- 1 January 2009
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2009 (1) , 320-325
Open AccessThe bridge between patient and doctor: the shift from CAM to integrative medicine
Integrative medicine (IM) has become a major challenge for doctors and nurses, as well as psychologists and many other disciplines involved in the endeavor to help patients to better tolerate the burden of toxic therapies and give patients tools so they can actively participate in their “salutogenesis.” IM encompasses psycho-oncology, acupuncture, and physical and mental exercises to restore vital capacities lost due to toxic therapies; furthermore, it aims to replenish nutritional and metabolic deficits during and after cancer treatment. IM gains an ever increasing importance in the face of the rapidly growing number of cancer survivors demanding more than just evidence-based diagnostic and therapeutic strategies. IM has to prove its value and justification by filling the gap between unproven methods of alternative medicine, still used by many cancer patients, and academic conventional medicine, which often does not satisfy the emotional and spiritual needs of cancer patients.
- 1 October 2007
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 21 (5) , 897-914
New Strategies for the Treatment of Advanced-Stage Hodgkin's Lymphoma
- 1 October 2007
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 21 (5) , 897-914
New Strategies for the Treatment of Advanced-Stage Hodgkin's Lymphoma
- 31 August 2007
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 37 (1) , 37-41
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
- 31 August 2007
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 37 (1) , 37-41
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?